ANTIMYCOTIC PHARMACEUTICAL COMPOSITION
    4.
    发明公开
    ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
    抗氧化药物组合物

    公开(公告)号:EP2470178A1

    公开(公告)日:2012-07-04

    申请号:EP10744747.6

    申请日:2010-07-29

    摘要: A pharmaceutical composition which comprises 1) a compound represented by the following general formula (1) and/or a salt thereof; and 2) a ketone such as methyl ethyl ketone. Preferably, the compound represented by the following general formula (1) is luliconazole, where R1═R2=a chlorine atom: where R1 and R2 each independently represents a hydrogen atom or a halogen atom, and at least one of R1 and R2 represents a halogen atom. The present invention provides a preparation excellent in solubilization stability for a compound represented by the general formula (1) and/or a salt thereof in low-temperature or high-temperature storage.

    摘要翻译: 1。一种药物组合物,其含有1)下述通式(1)表示的化合物和/或其盐; 和2)酮如甲乙酮。 优选地,下述通式(1)表示的化合物为卢立康唑,其中R 1 = R 2 =氯原子:其中R 1和R 2各自独立地表示氢原子或卤素原子,且R 1且R 2表示卤素原子。 本发明提供一种在低温或高温储存下对由通式(1)表示的化合物和/或其盐的溶解稳定性优异的制剂。

    ANTIMYCOTIC PHARMACEUTICAL COMPOSITION
    6.
    发明公开
    ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
    抗真菌的药物组合物

    公开(公告)号:EP2416757A2

    公开(公告)日:2012-02-15

    申请号:EP10714490.9

    申请日:2010-04-09

    IPC分类号: A61K9/08

    摘要: In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60° C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5° C. for 2 weeks after manufacture.